Caspofungin for invasive fungal infections: Combination treatment with liposomal amphotericin B in children undergoing hemopoietic stem cell transplantation

Pediatric Transplantation

Volumn 9, Issue 2, 2005, Pages 254-257

  Pancham, S ^a   Hemmaway, C ^a   New, H ^a   Albert, E ^a   Dokal, I ^a,b   Roberts, I A G ^a,b   McCloy, M ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Caspofungin; Fungal infections; Paediatrics; Transplantation

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ITRACONAZOLE; PIPERACILLIN PLUS TAZOBACTAM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VANCOMYCIN; VORICONAZOLE;

ADOLESCENT; ARTICLE; ASPERGILLOSIS; BLOOD TOXICITY; CASE REPORT; CHILD; ERADICATION THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVER TOXICITY; MYCOSIS; SIDE EFFECT;

ADOLESCENT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DRUG THERAPY, COMBINATION; FATAL OUTCOME; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; LIPOSOMES; MALE; MYCOSES; PEPTIDES, CYCLIC;

EID: 16444371000     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2005.00261.x     Document Type: Article

References (40)

1. CLARK T, HAJJEH RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002; 15: 569-574.
2. SHENEP JL, FLYNN PM. Pulmonary fungal infections in immunocompromised children. Curr Opin Pediatr 1997; 9: 213-218.
3. ABBASI S, SHENEP JL, HUGHES WT, FLYNN PM. Aspergillosis in children with cancer a 34 year experience. Clin Infect Dis 1999; 29: 1210-1219.
4. JOHANSEN HK, GØTZSCHE PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. The Cochrane Database of Systematic Reviews 2000, Issue 3. Art. no: CD000969. DOI: 10.1002/14651858. CD000969.
5. WALSH N. Liposomal Amphotericin B for empiric therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-1771.
6. GENTINA T, DE BOTTON S, ALFANDI S, et al. Combination antifungals for treatment of invasive Aspergillosis (IA) refractory to amphotericin B (amB) in leukaemia patients [abstract M-860]. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington DC: American Society for Microbiology, 2002. Available at: http://www.asm.org; last accessed, 12 March 2005.
7. THIEBAUT A Sr, ANTAL D. BREYSSE MC, PIVOT C. Refractory invasive fungal infections in patients with haematological malignancies: combination of new antifungal agents (voriconazole or caspofungin) with amphotericin B [abstract M-859]. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington DC: American Society for Microbiology, 2002. Available at: http://www.asmusa.org/mtgsrc/mtgs. htm
8. KONTOYIANNIS DP, HACHEM R, LEWIS RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal Amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with haematological malignancies. Cancer J 2003; 15: 292-299.
9. ELANJIKAL Z, SORENSEN J, SCHMIDT H, et al. Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis. Pediatr Infect Dis J 2003; 22: 653-656.
10. SALLMAN S, HEILMAN A, HEINKE F, et al. Caspofungin therapy for Aspergillus lung infection in a boy with chronic granulomatous disease. Pediatr Infect Dis J 2003; 22: 199-200.
11. FRANKLIN J, MC CORMICK J, FLYNN P. Retrospective study of the safety of caspofungin in immunocompromised children. Pediatr Infect Dis J 2003; 22: 747-749.
12. ASCIOGLU S, REX JH, DE PAUW B. Defining opportunistic fungal infections in Immunocompromised Patients with Cancer and Haemopoietic Stem Cell Transplants An International Consensus. Clin Infect Dis 2002; 34: 7-14.
13. MARR KA, CARTER RA, FULVIO C, et al. Epidemiology and Outcome of Mould Infections in Hemopoietic Stem Cell Transplant Recipients. Clin Infect Dis 2000; 34: 909-917.
14. RIBAUD P, CHASTANG C, LATGE J, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322-330.
15. LIN S, SCHRANZ J, TEUTSCH SM. Aspergillosis Case-Fatality Rate Systematic Review of the Literature. Clin Infect Dis 2001; 32: 358-366.
16. DENNING DW. Therapeutic Outcome In Invasive Aspergillosis. Clin Infect Dis 1996; 23: 608-615.
17. WALSH TJ, GONZALEZ C, LEYMAN C, et al. Invasive fungal infection in children. Adv Pediatr Infect Dis 1996; 11: 187-290.
18. BOMELBURG T, ROOS N, FEGELER W, RITTER F. Invasive aspergillosis during chemotherapy in children. Hematol Blood Transfus 1994; 36: 778-781.
19. RITTER J, ROOS N. Special aspects related to invasive fungal infections in children with cancer. Baillieres Clin Infect Dis 1995; 2: 179-204.
20. WALMSLEY S, DEVI S, KING S, SCHNEIDER R, RICHARDSON S, FORD-JONES L. Invasive Aspergillus infections in a pediatric hospital a ten-year review. Pediatr Infect Dis J 1993; 12: 673-682.
21. WALSH MH, BOWDEN RA, SANDLER E. Amphotericin B colloidal dispersion (ABCD) vs. amphotericin B in the empirical treatment of persisitently febrile neutropenic patients [abstract]. In: Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington DC: American Society for Microbiology, 1997: 381.
22. CHANOCK SJ, WALSH TJ. Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients. S15-S20. Bone Marrow Transplant 1996; 3: S15-S20.
23. PRENTICE HG, HANN IM, HERBRECHT R, et al. A randomized comparison of Liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711-718.
24. GROLL AH, MULLER FM, PISCITELLI SC, et al. Lipid formulations of amphotericin B clinical perspectives for the management of invasive fungal infections in children with cancer. Klin Paediatr 1998; 210: 264-273.
25. WHITE MH, ANAISSIE EJ, KUSNE S, et al. Amphotericin B colloidal dispersion vs amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997; 24: 635-642.
26. NOSKIN GA, PIETRIELLI L, COFFEY G, et al. Amphotericin B colloidal dispersion for the treatment of Candidemia in immunosuppressed patients. Clin Infect Dis 1998; 26: 461-467.
27. WALSH TJ, HIEMENZ JW, SEIBEL NL, et al. Amphotericin B lipid complex for invasive fungal infections analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-1396.
28. WINGARD JR. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 1997; 19: 343-347.
29. RINGDEN O. Clinical use of AmBisome with special emphasis on experience in children. Bone Marrow Transplant 1993; 12(4): S149-150.
30. ZOUBEK A, EMMINGER W, EMMINGER-SCHMIDMEIER W, et al. Conventional vs. Liposomal amphotericin B in immunosuppressed children [letter]. Pediatr Hematol Oncol 1992; 9: 187-190.
31. STEVENS DA, LEE JY. Analysis of compassionate use itraconazole use for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 1997; 157: 1857-1862.
32. DERESINSKI SC, STEVENS DA. Caspofungin (review). Clin Infect Dis 2003; 36: 1445-1457.
33. DENNING DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-1151.
34. KEATING GM, JARVIS B. Caspofungin. Drugs 2001; 61: 1121-1129.
35. MORA-DUARTE J, BETTS R, COLEMAN R, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
36. MAERTENS J, RAAD I, PETRIKKOS G, et al. Update of multicenter non comparative study of Caspofungin in adults with invasive aspergillosis refractory or intolerant to other antifungal agents: analysis of 90 patients [abstract M-856]. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington DC: American Society for Microbiology, 2002. Available at: http://www.asmusa.org/mtgsrc/mtgs. htm.
37. ARIKAN S, LOZANO-CHIU M, PAETZNICK V, et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245-247.
38. ALIFF TB, MASLAK PG, JURCIC JG, et al. Refractory Aspergillus pneumonia in patients with acute leukaemia successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: 1025-1032.
39. SABLE CA, NGUYEN BT, CHODAKEWITZ JA, et al. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002; 4: 25-30.
40. Sponsored by the National Cancer Institute: Study of Caspofungin Acetate in Immunocompromised Children with New-Onset Fever and Neutropenia. Protocol ID NCI-01-C-0084C. Available at: www.cancer.gov/clinicaltrials.